CXCL9 and CCL5 activated immune responses and enhanced ICB therapy in mouse model of ovary cancer (Dangaj et al., 2019), and the melanoma in CXCR3 knock-out mice exhibited decreased immune infiltration and poor prognosis (Korniejewska et al., 2011). This evidence concerns the gene CCL5 and ovarian cancer.